- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03606473
Brain Mechanisms in Young Adults (MHP)
Exploration of Mechanisms of Effects of Prenatal Cocaine Exposure in Young Adults
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Prenatal cocaine exposure (PCE) has consistently been associated with behavioral deficits through childhood, adolescence, and young adulthood in our ongoing study (PRO15080516 - Effects of Prenatal Cocaine Use: 25-Year Follow-Up). Further, 21-year-olds with PCE in our study were twice as likely to have been arrested as non-exposed offspring, were more likely to be diagnosed with Conduct Disorder, had higher disinhibition scores, were significantly more likely to use alcohol and marijuana earlier, and to have earlier sexual intercourse. The effects of PCE on the developing nervous system may cause changes in brain function that underlie these behavioral outcomes.
This study seeks to examine dopamine (DA) transmission in vivo, using positron emission tomography (PET) with [C-11]NPA, in striatal regions of interest in subjects who have a history of exposure to prenatal cocaine (PCE). We hypothesize that PCE is associated with increases in dopamine in the striatum relative to COMP. This may explain the impulsivity and high risk behaviors in PCE subjects
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
All potential subjects are current participants in the larger parent study entitled "Effects of Prenatal Cocaine Exposure: 25-Year Follow-Up", IRB PRO15080516. Participants are between 25 and 30 years of age.
Inclusion Criteria:
- Prenatal cocaine exposed subjects (PCE): Offspring exposed to prenatal cocaine (concurrent exposure to prenatal alcohol and tobacco are not exclusionary) as determined by detailed interviewing during pregnancy
- Comparison group (COMP): Offspring NOT exposed to prenatal cocaine (exposure to prenatal alcohol and tobacco are not exclusionary) as determined by detailed interviewing during pregnancy.
Exclusion criteria for both PCE and COMP groups:
- No current mania or psychosis based on current mental status exam and SCID-IV modules A (pages A18-A37) and B (pages B1-B8);
- No current cocaine, heroin, opioid, methadone, benzodiazepine, methamphetamine use (negative urine drug screen at both day of screening and the day of PET scan);
- No current use of cannabis (a negative urine drug screen on day of PET scan; Note: a positive cannabis urine on the day of screening will not be exclusionary because cannabis tends to be used for recreation; and it takes a long time for it turn negative because it is released from fat cells in body long after subject has quit; and it has been shown to not impact amphetamine-induced dopamine release in prior studies);
- Not currently taking prescription or over the counter medications that can alter monoamine transmission in the brain or interact with the d-amphetamine challenge or alter amphetamine concentrations (major CYP2D6 inhibitors such as fluoxetine, thioridazine, terbinafine etc., as well as pseudo-ephedrine, atomoxetine, SSRIs, etc.);
- No use of acidifying (fruit juice; beverages; ascorbic acid) and alkalinizing agents (such as sodium bicarbonate) that alter amphetamine concentrations at least 12 hrs before PET scan day;
- No current or past severe medical or neurological illnesses such as seizure disorders, head injury with prolonged loss of consciousness, hypertension, prior MI, CAD etc., (determined by physician investigator's elicited medical history, physical exam, review of labs, and EKG results);
- Not currently pregnant (serum pregnancy test at screening) or breastfeeding;
- No history of radioactivity exposure via prior nuclear medicine studies or occupational exposure in past 12 months;
- No metallic objects in the body that are contraindicated for MRI;
- SBP > 135, DBP > 85, and/or HR ≤ 50 or ≥ 100 (documented before the PET scans; Note: it is not unusual to have to repeat screening vital signs in subjects' because some subjects tend to have white coat syndrome and present with elevated vitals at screening, which later normalizes);
- No first-degree relative with an MI or stroke or TIA prior to 50 years of age;
- No first-degree relative with psychosis or mania.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Prenatal cocaine exposed subjects
[C-11]NPA PET at baseline and post d-amphetamine
|
is used to stimulate dopamine release in the brain
PET radiotracer
|
EXPERIMENTAL: Comparison subjects
[C-11]NPA PET at baseline and post d-amphetamine
|
is used to stimulate dopamine release in the brain
PET radiotracer
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent change in Binding potential (BPnd)
Time Frame: Baseline BPnd (time 0) and Post-amphetamine BPnd (time 3 hours
|
DELTA BPND
|
Baseline BPnd (time 0) and Post-amphetamine BPnd (time 3 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Cocaine-Related Disorders
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Sympathomimetics
- Adrenergic Uptake Inhibitors
- Amphetamine
- Dextroamphetamine
Other Study ID Numbers
- PRO17080203
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cocaine-Related Disorders
-
Baylor College of MedicineNational Institute on Drug Abuse (NIDA)CompletedSubstance Abuse | Cocaine Dependence | Cocaine Abuse | Cocaine AddictionUnited States
-
Baylor College of MedicineNational Institute on Drug Abuse (NIDA)CompletedSubstance Abuse | Cocaine Dependence | Cocaine Abuse | Cocaine AddictionUnited States
-
Baylor College of MedicineNational Institute on Drug Abuse (NIDA)CompletedSubstance Abuse | Cocaine Dependence | Cocaine Abuse | Cocaine AddictionUnited States
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA); Columbia UniversityNot yet recruitingCocaine Use Disorder | Cocaine Dependence | Cocaine Use | Cocaine Use Disorder, Moderate | Cocaine Use Disorder, Severe
-
Tonix Pharmaceuticals, Inc.National Institute on Drug Abuse (NIDA); PremierNot yet recruitingCocaine Use | Cocaine Abuse | Cocaine Adverse Reaction | Cocaine Intoxication | Cocaine Toxicity
-
Temple UniversityNational Institute on Drug Abuse (NIDA); University of PennsylvaniaCompletedCocaine-Related Disorders | Cocaine Dependence | Cocaine Abuse | Cocaine AddictionUnited States
-
Baylor College of MedicineNational Institute on Drug Abuse (NIDA)CompletedSubstance Abuse | Cocaine Dependence | Cocaine Abuse | Cocaine AddictionUnited States
-
ITAB - Institute for Advanced Biomedical TechnologiesNot yet recruitingCocaine Dependence | Cocaine Use | Cocaine Abuse | NeurotropismItaly
-
University of VirginiaRecruitingCocaine Use Disorder | Cocaine Dependence | Ultrasound | Cocaine AbuseUnited States
-
University Hospital Center of MartiniqueUnknown
Clinical Trials on d-amphetamine
-
University Hospital, Basel, SwitzerlandCompleted
-
University of Illinois at ChicagoThe University of Texas Health Science Center, HoustonRecruiting
-
ShireCompletedAttention Deficit Disorder With HyperactivityUnited States
-
ShireCompletedAttention Deficit Disorder With Hyperactivity
-
The University of Texas Health Science Center,...Emory UniversityCompleted
-
ShireCompletedAttention Deficit Disorder With Hyperactivity
-
Noven Pharmaceuticals, Inc.CompletedAttention Deficit Hyperactivity DisorderUnited States
-
ShireCompletedAttention Deficit Disorder With Hyperactivity
-
University of ChicagoCompleted
-
Janssen-Cilag International NVCompleted